Literature DB >> 24190862

Wnt pathway in osteosarcoma, from oncogenic to therapeutic.

Yu Cai1, Tiange Cai, Yan Chen.   

Abstract

Osteosarcoma is the most common malignant bone tumor in children and adolescents. Although pathologic characteristics of this disease are clear and well established, much remains to be understood about this tumor, particularly at the molecular signaling level. Secreted signaling molecules of the Wnt family have been widely investigated and found to play a central role in controlling embryonic bone development, bone mass, and postnatal bone regeneration. A variety of studies also suggest that Wnt signaling pathway is closely associated with bone malignancies, including breast or prostate cancer induced bone metastasis, multiple myeloma, as well as osteosarcoma. Here, we provide an overview of the role of Wnt signaling pathway in osteosarcoma development and progression, highlighting the aberrant activation of Wnt pathway in this bone malignancy. We also discuss the potential therapeutic applications for the treatment of osteosarcoma targeting Wnt pathway.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  BETA-CATENIN; OSTEOSARCOMA; Wnt

Mesh:

Substances:

Year:  2014        PMID: 24190862     DOI: 10.1002/jcb.24708

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  46 in total

1.  The tumor suppressive role of RASSF1A in osteosarcoma through the Wnt signaling pathway.

Authors:  Wei-Guo Wang; Shi-Jie Chen; Jin-Shen He; Jing-Song Li; Xiao-Fang Zang
Journal:  Tumour Biol       Date:  2016-01-11

Review 2.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

3.  Gene expression profile comparison between colorectal cancer and adjacent normal tissues.

Authors:  Qian Yang; Maohui Feng; Xiang Ma; Huachi Li; Wei Xie
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

Review 4.  Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.

Authors:  D Matthew Gianferante; Lisa Mirabello; Sharon A Savage
Journal:  Nat Rev Endocrinol       Date:  2017-03-24       Impact factor: 43.330

Review 5.  Molecular genetics of osteosarcoma.

Authors:  Kirby Rickel; Fang Fang; Jianning Tao
Journal:  Bone       Date:  2016-10-17       Impact factor: 4.398

6.  Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.

Authors:  Motonari Nomura; Nino Rainusso; Yi-Chien Lee; Brian Dawson; Cristian Coarfa; Ruolan Han; Jeffrey L Larson; Ryan Shuck; Lyazat Kurenbekova; Jason T Yustein
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

Review 7.  Deciphering signaling networks in osteosarcoma pathobiology.

Authors:  Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-06

Review 8.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

Review 9.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

10.  Mesenchymal Tumors Can Derive from Ng2/Cspg4-Expressing Pericytes with β-Catenin Modulating the Neoplastic Phenotype.

Authors:  Shingo Sato; Yuning J Tang; Qingxia Wei; Makoto Hirata; Angela Weng; Ilkyu Han; Atsushi Okawa; Shu Takeda; Heather Whetstone; Puvindran Nadesan; David G Kirsch; Jay S Wunder; Benjamin A Alman
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.